4D-150

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug Name4D-150
Drug Alias NameDual-transgene, intravitreal gene therapy（4d Molecular）4D-150
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV-R100 vector
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitorsVascular endothelial growth factor B inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor AVascular endothelial growth factor B
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator Companies4d Molecular Therapeutics Inc
China Registration ClassN/A

Develop Information

Active Companies4d Molecular Therapeutics IncOtsuka Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A